News Column

ARCA biopharma Elects Dan Mitchell to Its Board

February 17, 2014

ARCA biopharma, Inc., a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, has announced that Dan Mitchell has been appointed to the Company's Board of Directors.

Mitchell will serve on the Audit and Nominating and Corporate Governance Committees of the Board of Directors, the Company noted in a release.

ARCA said that Mitchell founded and is a Manager of Sequel Venture Partners, a venture capital firm formed in January 1997. Prior to founding Sequel Venture Partners, Mitchell was a founder in 1986 of Capital Health Venture Partners, a health care focused venture capital firm, where he was a General Partner until 2006. On behalf of Sequel Ventures, Mitchell led the 1998 Series A financing that initially funded Myogen, Inc., a biopharmaceutical company focused on cardiovascular diseases, participated in subsequent financing rounds and served on the board of directors until Myogen's was acquired in 2006. He served on the board of directors of Replidyne, Inc., a publicly traded pharmaceutical company, from 2002 until the company was acquired in 2009. Mitchell currently serves on the board of directors of several private companies. Mitchell holds a B.S. from the University of Illinois and an M.B.A. from the University of California at Berkeley.

"We are honored to have Dan join the ARCA Board of Directors," said Dr. Michael R. Bristow, President and Chief Executive Officer of ARCA. "With his significant expertise and experience in identifying investment worthy companies and helping to advise those companies in managing their growth, Dan will be a valuable addition to the ARCA Board as we continue the development of Gencaro and look to deliver value to our stockholders."

"I am delighted to join the Board of ARCA at this important point in its development," said Mitchell. "The imminent initiation of the GENETIC-AF trial evaluating ARCA's Gencaro as potentially the first genetically-targeted atrial fibrillation prevention treatment is a tremendous step in hopefully addressing what we believe is an unmet medical need for new atrial fibrillation treatments. ARCA's personalized medicine approach to drug development has identified both the compound and the regulatory pathway to potentially achieve that goal."

((Comments on this story may be sent to

For more stories on investments and markets, please see HispanicBusiness' Finance Channel

Source: Health & Beauty Close - Up

Story Tools